The long road to colorectal cancer therapy: Searching for the right signals

Drug Resistance Updates

Volumn 13, Issue 1-2, 2010, Pages 44-56

  Hollande, Frédéric ^a,b   Pannequin, Julie ^a,b   Joubert, Dominique ^a,b  

^a INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Biomarkers; c MET; Colorectal cancer; Hedgehog signaling; IGF 1R; Monoclonal antibodies; Signaling pathways; Src family; Tyrosine kinase inhibitors; Wnt signaling

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; AFLIBERCEPT; AMG 102; AMG 479; AXITINIB; BAY 734506; BEVACIZUMAB; BGT 226; BIOLOGICAL MARKER; BOSUTINIB; CEDIRANIB; CETUXIMAB; DASATINIB; DULANERMIN; GDC 0449; GDC 0973; GDC 0980; GEFITINIB; IMC 1121B; IMC 18F1; LAPATINIB; LINIFANIB; MOTESANIB; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NIMOTUZUMAB; PANITUMUMAB; PAZOPANIB; PERIFOSINE; PRO 95780; PROTEIN TYROSINE KINASE; RAMUCIRUMAB; SONIC HEDGEHOG PROTEIN; SORAFENIB; SUNITINIB; TB 403; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN; XL 765; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE;

ARTICLE; CANCER PATIENT; CANCER STAGING; COLORECTAL CANCER; DRUG EFFICACY; HUMAN; METASTASIS; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN FAMILY; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH;

EID: 77950867091     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2009.01.002     Document Type: Article

References (191)

1. Aaltonen L.A., Salovaara R., Kristo P., Canzian F., Hemminki A., Peltomaki P., et al. Incidence of hereditary non-polyposis colorectal cancer and the feasibility of molecular screening for the disease. New Engl. J. Med. 338 (1998) 1481-1487
2. Aligayer H., Boyd D.D., Heiss M.M., Abdalla E.K., Curley S.A., and Gallick G.E. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 94 (2002) 344-351
3. Allegra C.J., Yothers G., O'Connell M.J., et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J. Clin. Oncol. 27 (2009) 3385-3390
4. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26 (2008) 1626-1634
5. André T., Boni C., et al. Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. New Engl. J. Med. 350 (2004) 2343-2351
6. Aschele C., Bergamo F., and Lonardi S. Chemotherapy for operable and advanced colorectal cancer. Cancer Treat. Rev. 35 (2009) 509-516
7. Bardelli A., and Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. (2010) 10.1200/JCO.2009.24.6116
8. Barker N., and Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat. Rev. Drug Discov. 5 (2006) 997-1014
9. Barker N., van Es J.H., Kuipers J., et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449 (2007) 1003-1007
10. Barker N., Ridgway R.A., van Es J.H., et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457 (2009) 608-611
11. Baselga J., and Rosen N. Determinants of resistance to anti-epidermal growth factor receptor agents. J. Clin. Oncol. 26 (2008) 1582-1584
12. Becker L., Huang Q., and Mashimo H. Immunostaining of LGr5, an intestinal stem cell marker, in normal and premalignant human gatrointestinal tissue. Scientific World J. 23 (2008) 1168-1176
13. Beier D., Rohrl S., Pillai D.R., et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res. 68 (2008) 5706-5715
14. Benistant C., Chapuis H., and Roche S. A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 19 (2000) 5083-5090
15. Bergers G., and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8 (2008) 592-603
16. Bertagnolli M.M. The forest and the trees: pathways and proteins as colorectal cancer biomarkers. J. Clin. Oncol. 27 (2009) 5866-5867
17. Bianco R., Damiano V., Gelardi T., Daniele G., Ciardiello F., and Tortora G. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. Curr. Pharm. Des. 13 (2007) 3358-3367
18. Bibeau F., Lopez-Crapez E., Di Fiore F., et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 27 (2009) 1122-1129
19. Birchmeier C., Birchmeier W., Gherardi E., and Van de Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4 (2003) 915-925
20. Boland W.K., and Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin. Biol. Ther. 9 (2009) 1199-1206
21. Bolen J.B., Veillette A., Schwartz A.M., DeSeau V., and Rosen N. Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc. Natl. Acad. Sci. (U.S.A.) 84 (1987) 2251-2255
22. Bordonaro M., Lazarova D.L., and Sartorelli A.C. Hyperinduction of Wnt activity: a new paradigm for the treatment of colorectal cancer?. Oncol. Res. 17 (2008) 1-9
23. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res. 49 (1989) 4682-4689
24. Brabletz T., Jung A., Spaderna S., Hlubek F., and Kirchner T. Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat. Rev. Cancer 5 (2005) 744-749
25. Carpten J.D., Faber A.L., Horn C., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448 (2007) 439-444
26. Chau I., and Cunningham D. Treatment in advanced colorectal cancer: what, when and how?. Br. J. Cancer 100 (2009) 1704-1719
27. Chen H.X., and Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 6 (2009) 465-477
28. Chen B., Dodge M.E., Tang W., et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 5 (2009) 100-107
29. Chu E. New treatment strategies for metastatic colorectal cancer. CMP Med. (2008)
30. Church J., Kiringoda R., and LaGuardia L. Inherited colorectal cancer registries in the United States. Dis. Colon Rectum 47 (2004) 674-678
31. Comella P., Casaretti R., Avallone A., and Franco L. Optimizing the management of metastatic colorectal cancer. Crit. Rev. Oncol. Hematol. (2009) 10.1016/jcritrevonc.2009.09.008
32. Comoglio P.M., Giordano S., and Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 7 (2008) 504-516
33. Crawford Y., and Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res. 335 (2009) 261-269
34. Crawford Y., Kasman I., Yu L., Zhong C., Wu X., Modrusan Z., Kaminker J., and Ferrara N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15 (2009) 21-34
35. Croker A.K., and Allan A.L. Cancer stem cells: implications for the progression and treatment of metastatic disease. J. Cell. Mol. Med. 12 (2008) 374-390
36. Crosnier C., Stamataki D., and Lewis J. Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat. Rev. Genet. 7 (2006) 349-359
37. Cully M., You H., Levine A.J., and Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6 (2006) 184-192
38. Dalerba P., Dylla S.J., and Park I.K. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. (U.S.A.) 104 (2007) 10158-10163
39. de Gramont A., Haller D.G., Sargent D.J., Tabernero J., Matheson A., and Schilsky R.L. Toward efficient trials in colorectal cancer: the ARCAD clinical trials program. J. Clin. Oncol. (2009) 10.1200/JCO.2009.25.2544
40. Dehm S.M., and Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. Biochem. Cell Biol. 82 (2004) 263-274
41. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26 (2008) 5705-5712
42. Dylla S.J., Beviglia L., Park I.K., et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 3 (2008) e2428
43. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., and Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 (2009) 232-239
44. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767
45. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
46. Fields A.L., Keller A., Schwartzberg L., et al. Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J. Clin. Oncol. 27 (2009) 1941-1947
47. Fisher G.A., et al. A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Clin. Cancer Res. 14 (2008) 7074-7079
48. Fre S., Huyghe M., Mourikis P., Robine S., Louvard D., and Artavanis-Tsakonas S. Notch signals control the fate of immature progenitor cells in the intestine. Nature 435 (2005) 964-968
49. Frost A., et al. J. Clin Oncol. 26 May (20) suppl. (2008) (Abstr 2558)
50. Garlich J.R., De P., Dey N., et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug. SF1126, with antitumor and antiangiogenic activity. Cancer Res. 68 (2008) 206-215
51. Giannopoulou E., Antonacopoulou A., Floratou K., Papavassiliou A.G., and Kalofonos H.P. Dual targeting of EGFR and HER-2 in colon cancer cell lines. Cancer Chemother. Pharmacol. 63 (2009) 973-981
52. Goldfinger L.E. Choose your own path: specificity in Ras GTPase signaling. Mol. Biosyst. 4 (2008) 293-299
53. Grady W.M., and Carethers J.M. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135 (2008) 1079-1099
54. Grange J.M., Stanford J.L., and Stanford C.A. Campbell De Morgan's 'Observations on cancer', and their relevance today. J. R. Soc. Med. 95 (2002) 296-299
55. Gravalos C., Garcia-Escobar I., Garcia-Alfonso P., Cassinello J., Malon D., and Carrato A. Adjuvant chemotherapy for stages II, III and IV of colon cancer. Clin. Transl. Oncol. 11 (2009) 526-533
56. Greenberg J.I., Shields D.J., Barillas S.G., et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456 (2008) 809-813
57. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., and Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138 (2009) 645-659
58. Hakam A., Yeatman T.J., Lu L., Mora L., Marcet G., Nicosia S.V., Karl R.C., and Coppola D. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum. Pathol. 30 (1999) 1128-1133
59. Hecht J.R., Trarbach T., Jaeger E., et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J. Clin. Oncol. 23 (2005) LBA3 (Abstract)
60. Heinemann V., Stintzing S., Kirchner T., Boeck S., and Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat. Rev. 35 (2009) 262-271
61. Herbst R.S. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin. Investig. Drugs 11 (2002) 837-849
62. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., and Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1 (2007) 313-323
63. Hewish M., Chau I., and Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat. Anticancer Drug Discov. 4 (2009) 54-72
64. Hilgard P., Klenner T., Stekar J., Nossner G., Kutscher B., and Engel J. D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur. J. Cancer 33 (1997) 442-446
65. Hirsch H.A., Iliopoulos D., Tsichlis P.N., and Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69 (2009) 7507-7511
66. Hsiao S.J., and Smith S. Tankyrase function at telomeres, spindle poles, and beyond. Biochimie 90 (2008) 83-92
67. Hsu J.Y., and Wakelee H.A. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 23 (2009) 289-304
68. Huang S.M., Mishina Y.M., Liu S., Cheung A., Stegmeier F., Michaud G.A., et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461 (2009) 614-620
69. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl. J. Med. 350 (2004) 2335-2342
70. Hurwitz H.I., Dowlati A., Saini S., et al. Phase I trial of pazopanib in patients with advanced cancer. Clin. Cancer Res. 15 (2009) 4220-4227
71. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5 (2005) 341-354
72. Ibn-Sîna. The Canon of Medicine (1999), Kazi Publications, Chicago
73. Jalving M., de Jong S., Koornstra J.J., et al. TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin. Cancer Res. 12 (2006) 4350-4356
74. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 59 (2009) 225-249
75. Jiang B.H., and Liu L.Z. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist. Updat. 11 (2008) 63-76
76. Jones S., Chen W.D., Parmigiani G., et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl. Acad. Sci. (U.S.A.) 105 (2008) 4283-4288
77. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. New Engl. J. Med. 357 (2007) 2040-2048
78. Joyce J.A. Therapeutic targeting of the tumor microenvironment. Cancer Cell 7 (2005) 513-520
79. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., Griffing S., and Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21 (2003) 60-65
80. Kalderon D. Transducing the hedgehog signal. Cell 103 (2000) 371-374
81. Kammula U.S., Kuntz E.J., Francone T.D., et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 248 (2007) 219-228
82. Karakosta A., Golias C., Charalabopoulos A., Peschos D., Batistatou A., and Charalabopoulos K. Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia. J. Exp. Clin. Cancer Res. 24 (2005) 505-514
83. Kim L.C., Song L., and Haura E.B. Src kinases as therapeutic targets for cancer. Nat. Rev. Clin. Oncol. 6 (2009) 587-595
84. Kitisin K., and Mishra L. Molecular biology of colorectal cancer: new targets. Semin. Oncol. 33 (2006) S14-23
85. Knight Z.A., Gonzalez B., Feldman M.E., et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125 (2006) 733-747
86. Knight Z.A., Lin H., and Shokat K.M. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10 (2010) 130-137
87. Knudsen B.S., and Van de Woude G. Showering c-MET-dependent cancers with drugs. Curr. Opin. Genet. Dev. 18 (2008) 87-96
88. Koehne C., Bajetta E., Lin E., Van Cutsem E., Hecht J., Douillard J., Moore M., et al. Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). J. Clin. Oncol. 24 (2006) 3508 (Abstract)
89. Konstantinopoulos P.A., Karamouzis M.V., and Papavassiliou A.G. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat. Rev. Drug Discov. 6 (2007) 541-555
90. Kopetz S., Shah A.N., and Gallick G.E. Src continues aging: current and future clinical directions. Clin. Cancer Res. 13 (2007) 7232-7236
91. Korinek V., Barker N., Morin P.J., van Wichen D., de Weger R., Kinzler K.W., Vogelstein B., and Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275 (1997) 1784-1787
92. Krupitskaya Y., and Wakelee H.A. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr. Opin. Invest. Drugs 10 (2009) 597-605
93. LaBonte M.J., Manegold P.C., Wilson P.M., Fazzone W., Louie S.G., Lenz H.J., and Ladner R.D. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Int. J. Cancer 125 (2009) 2957-2969
94. Laurent-Puig P., Cayre A., Manceau G., Buc E., Bachet J.B., Lecomte T., et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol. 27 (2009) 5924-5930
95. Le Tourneau C., Vidal L., and Siu L.L. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. Drug Resist. Updat. 11 (2008) 99-109
96. Li F., Tiede B., Massague J., and Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 17 (2007) 3-14
97. Li X., Lewis M.T., Huang J., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 100 (2008) 672-679
98. Li C., Iida M., Dunn E.F., Ghia A.J., and Wheeler D.L. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28 (2009) 3801-3813
99. Lieberman D.A. Clinical practice. Screening for colorectal cancer. New Engl. J. Med. 361 (2009) 1179-1187
100. Lievre A., Bachet J.B., Boige V., Cayre A., Le Corre D., Buc E., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26 (2008) 374-379
101. Liu P., Cheng H., Roberts T.M., and Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8 (2009) 627-644
102. Lockhart A.C., Rothenberg M.L., Dupont J., Cooper W., Chevalier P., Sternas L., et al. Phase I study of intravenous vascular endothelial growth factor Trap. Aflibercept, in patients with advanced solid tumors. J. Clin. Oncol. 28 (2009) 207-214
103. LoPiccolo J., Blumenthal G.M., Bernstein W.B., and Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 11 (2008) 32-50
104. Los M., Roodhart J.M., and Voest E.E. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12 (2007) 443-450
105. Loupakis F., Pollina L., Stasi I., Ruzzo A., Scartozzi M., Santini D., et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J. Clin. Oncol. 27 (2009) 2622-2629
106. Lynch H.T., Lynch P.M., Lanspa S.J., Snyder C.L., Lynch J.F., and Boland C.R. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis and medicolegal ramifications. Clin. Genet. 76 (2009) 1-18
107. Ma P.C., Maulik G., Christensen J., and Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metast. Rev. 22 (2003) 309-325
108. MacDonald B.T., Tamai K., and He X. Wnt/beta-catenin signaling: components, mechanisms and diseases. Dev. Cell 17 (2009) 9-26
109. Mack G.S. FDA holds court on post hoc data linking KRAS status to drug response. Nat. Biotechnol. 27 (2009) 110-112
110. Mahalingam D., Keane M., Pirianov G., Mehmet H., Samali A., and Szegezdi E. Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines. Br. J. Cancer 100 (2009) 1415-1424
111. Maira S.M., Stauffer F., Brueggen J., et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7 (2008) 1851-1863
112. Mandrekar S.J., and Sargent D.J. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J. Clin. Oncol. 27 (2009) 4027-4034
113. Marone R., Cmiljanovic V., Giese B., and Wymann M.P. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim. Biophys. Acta 1784 (2008) 159-185
114. Medina V., Calvo M.B., Diaz-Prado S., and Espada J. Hedgehog signalling as a target in cancer stem cells. Clin. Transl. Oncol. 11 (2009) 199-207
115. Mendelsohn J., and Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21 (2003) 2787-2799
116. Montagnani F., Migali C., and Fiorentini G. Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point?. J. Clin. Oncol. 27 (2009) e132-133 (author reply e134-135)
117. Monzo M., Moreno I., Artells R., et al. Sonic hedgehog mRNA expression by real-time quantitative PCR in normal and tumor tissues from colorectal cancer patients. Cancer Lett. 233 (2006) 117-123
118. Morgillo F., and Lee H.Y. Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist. Updat. 8 (2005) 298-310
119. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., and Kinzler K.W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275 (1997) 1787-1790
120. Mross K., Steinbild S., Baas F., et al. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur. J. Cancer 43 (2007) 55-63
121. Nakamura T., Tsuchiya K., and Watanabe M. Crosstalk between Wnt and Notch signaling in intestinal epithelial cell fate decision. J. Gastroenterol. 42 (2007) 705-710
122. O'Brien C.A., Pollett A., Gallinger S., and Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445 (2007) 106-110
123. O'Connell M.J. Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in. J. Clin. Oncol. 27 (2009) 3082-3084
124. Olaussen K.A., Commo F., Tailler M., et al. Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. Oncogene 28 (2009) 4249-4260
125. Olson J.S. The History of Cancer; An Annotated Bibliography (1989), Greenwood Press
126. O'Neil B.H., and Goldberg R.M. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist 13 (2008) 1074-1083
127. Paez-Ribes M., Allen E., Hudock J., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 (2009) 220-231
128. Pinol V., Andreu M., Castells A., Paya A., Bessa X., and Rodrigo J. Frequency of hereditary non-polyposis colorectal cancer and other colorectal cancer familial forms in Spain: a multicentre, prospective, nationwide study. Eur. J. Gastroenterol. Hepatol. 16 (2004) 39-45
129. Pinto D., and Clevers H. Wnt control of stem cells and differentiation in the intestinal epithelium. Exp. Cell Res. 306 (2005) 357-363
130. Pozzo C., Barone C., and Kemeny N.E. Advances in neoadjuvant therapy for colorectal cancer with liver metastases. Cancer Treat. Rev. 34 (2008) 293-301
131. Price T.J., Lipton L., McGreivy J., McCoy S., Sun Y.N., and Rosenthal M.A. Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. Br. J. Cancer 99 (2008) 1387-1394
132. Punt C.J., and Tol J. More is less-combining targeted therapies in metastatic colorectal cancer. Nat. Rev. Clin. Oncol. 6 (2009) 731-733
133. Radtke F., and Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 307 (2005) 1904-1909
134. Rennel E., Waine E., Guan H., et al. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br. J. Cancer 98 (2008) 1250-1257
135. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., and De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 445 (2007) 111-115
136. Richman S.D., Seymour M.T., Chambers P., et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J. Clin. Oncol. 27 (2009) 5931-5937
137. Robarge K.D., Brunton S.A., Castanedo G.M., et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg. Med. Chem. Lett. 19 (2009) 5576-5581
138. Rodilla V., Villanueva A., Obrador-Hevia A., et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc. Natl. Acad. Sci. (U.S.A.) 106 (2009) 6315-6320
139. Rubin L.L., and de Sauvage F.J. Targeting the Hedgehog pathway in cancer. Nat. Rev. Drug Discov. 5 (2006) 1026-1033
140. Rustgi A.K. The genetics of hereditary colon cancer. Genes Dev. 21 (2007) 2525-2538
141. Salovaara R., Loukola A., Kristo P., et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J. Clin. Oncol. 18 (2000) 2193-2200
142. Saltz L.B., Rosen L.S., Marshall J.L., et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J. Clin. Oncol. 25 (2007) 4793-4799
143. Samuels Y., Wang Z., Bardelli A., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
144. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
145. Sato T., Vries R.G., Snippert H.J., et al. Single LGr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459 (2009) 262-265
146. Schmidt M., De Maziere A., Smyczek T., Gray A., Parker L., Filvaroff E., et al. The role of Egfl7 in vascular morphogenesis. Novartis Found. Symp. 283 (2007) 18-28 (discussion 28-36, 238-241)
147. Schmoll H.J., and Arnold D. When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab. J. Clin. Oncol. 27 (2009) 1926-1929
148. Schneider B.P., Radovich M., and Miller K.D. The role of vascular endothelial growth factor genetic variability in cancer. Clin. Cancer Res. 15 (2009) 5297-5302
149. Segal N.H., and Saltz L.B. Evolving treatment of advanced colon cancer. Annu. Rev. Med. 60 (2009) 207-219
150. Shannon A.M., Telfer B.A., Smith P.D., et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts. Clin. Cancer Res. 15 (2009) 6619-6629
151. Sharma S.V., and Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21 (2007) 3214-3231
152. Sharma S., Abhyankar V., Burgess R.E., et al. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann. Oncol. (2009) 10.1093/annonc/mdp489
153. Shojaei F., and Ferrara N. Role of the microenvironment in tumor growth and in refractractoriness/resistance to anti-angiogenic therapies. Drug Resist. Updat. 11 (2008) 219-230
154. Siena S., Sartore-Bianchi A., Di Nicolantonio F., Balfour J., and Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl. Cancer Inst. 101 (2009) 1308-1324
155. Snippert H.J., van Es J.H., van den Born M., et al. Prominin-1/CD133 marks stem cells and early progenitors in mouse small intestine. Gastroenterology 136 (2009) 2187-2194
156. Spicer J. Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience. Curr. Opin. Mol. Ther. 7 (2005) 182-191
157. Stockmann C., Doedens A., Weidemann A., Zhang N., Takeda N., Greenberg J.I., Cheresh D.A., and Johnson R.S. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456 (2008) 814-818
158. Taipale J., and Beachy P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature 411 (2001) 349-354
159. Takayama T., Miyanishi K., Hayashi T., Sato Y., and Niitsu Y. Colorectal cancer: genetics of development and metastasis. J. Gastroenterol. 41 (2006) 185-192
160. Takeuchi H., Bilchik A., Saha S., et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin. Cancer Res. 9 (2003) 1480-1488
161. Termuhlen P.M., Curley S.A., Talamonti M.S., Saboorian M.H., and Gallick G.E. Site-specific differences in pp60c-src activity in human colorectal metastases. J. Surg. Res. 54 (1993) 293-298
162. Tol J., Koopman M., Rodenburg C.J., Cats A., Creemers G.J., Schrama J.G., et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann. Oncol. 19 (2008) 734-738
163. Tolcher A.W., Sarantopoulos J., Patnaik A., et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 27 (2009) 5800-5807
164. Tortora G., Bianco R., Daniele G., Ciardiello F., McCubrey J.A., Ricciardi M.R., et al. Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist. Updat. 10 (2007) 81-100
165. Trusolino L., and Comoglio P.M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer 2 (2002) 289-300
166. Van Cutsem E., Nowacki M., Lang I., et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J. Clin. Oncol. 25 (2007) 4000 (Abstract)
167. Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25 (2007) 1658-1664
168. Van Cutsem E., Köhne C.H., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New Engl. J. Med. 360 (2009) 1408-1417
169. Van den Eynde M., and Hendlisz A. Treatment of colorectal liver metastases: a review. Rev. Recent Clin. Trials 4 (2009) 56-62
170. Van der Flier L.G., Sabates-Bellver J., Oving I., Haegebarth A., De Palo M., Anti M., et al. The intestinal Wnt/TCF signature. Gastroenterology 132 (2007) 628-632
171. Van Es J.H., and Clevers H. Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease. Trends Mol. Med. 11 (2005) 496-502
172. Varjosalo M., and Taipale J. Hedgehog signaling. J. Cell Sci. 120 (2007) 3-6
173. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2 (2002) 489-501
174. Von Hoff D.D., LoRusso P.M., Rudin C.M., et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. New Engl. J. Med. 361 (2009) 1164-1172
175. Wakeling A.E., Guy S.P., Woodburn J.R., Ashton S.E., Curry B.J., Barker A.J., and Gibson K.H. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62 (2002) 5749-5754
176. Wang Y., and Sun Y. Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. Curr. Cancer Drug Targets 2 (2002) 191-207
177. Weber M.M., Fottner C., Liu S.B., Jung M.C., Engelhardt D., and Baretton G.B. Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95 (2002) 2086-2095
178. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297 (2002) 63-64
179. Wheeler D.L., and Dunn E.F. BB, a novel epidermal growth factor receptor inhibitor. Cancer Biol. Ther. 8 (2009) 1648-1650
180. Wheeler D.L., Iida M., and Dunn E.F. The role of Src in solid tumors. Oncologist 14 (2009) 667-678
181. Wilhelm S.M., Adnane L., Newell P., Villanueva A., Llovet J.M., and Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7 (2008) 3129-3140
182. Wolmark N., Yothers G., O'Connell M.J., et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08. J. Clin. Oncol. 27 (2009) LBA4 (Abstract)
183. Wong J.J., Hawkins N.J., and Ward R.L. Colorectal cancer: a model for epigenetic tumorigenesis. Gut 56 (2007) 140-148
184. Wood J.M., Bold G., Buchdunger E., Cozens R., Ferrari S., Frei J., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60 (2000) 2178-2189
185. Woodburn J.R., Barker A.J., Wakeling A., et al. 6-Amino-4-(3-methyiphenylamino)-quinazoline: an EGF receptor tyrosine kinase inhibitor with activity in a range of human tumour xenografts. Proc. Am. Soc. Clin. Oncol. (1996) 390
186. Xiao G.H., Jeffers M., Bellacosa A., Mitsuuchi Y., Van de Woude G.F., and Testa J.R. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Natl. Acad. Sci. (U.S.A.) 98 (2001) 247-252
187. Xu L., Duda D.G., di Tomaso E., Ancukiewicz M., Chung D.C., Lauwers G.Y., et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res. 69 (2009) 7905-7910
188. Yamamoto N., Tamura T., Yamamoto N., et al. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 64 (2009) 1165-1172
189. Zeng Z.S., Weiser M.R., Kuntz E., Chen C.T., Khan S.A., Forslund A., et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 265 (2008) 258-269
190. Zhang Y., Laterra J., and Pomper M.G. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia 11 (2009) 96-101
191. Zhou B.B., Zhang H., Damelin M., Geles K.G., Grindley J.C., and Dirks P.B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 8 (2009) 806-823